PMID- 34676669
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20220131
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 12
IP  - 23
DP  - 2021 Dec
TI  - Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for 
      locally advanced non-small cell lung cancer: A systematic review and 
      meta-analysis.
PG  - 3208-3215
LID - 10.1111/1759-7714.14188 [doi]
AB  - BACKGROUND: We aimed to clarify the benefits of the addition of rh-endostatin 
      into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced 
      non-small cell lung cancer (NSCLC) by a meta-analysis. METHODS: PubMed, Embase, 
      Cochrane Central Register of Controlled Trials, Wanfang and Chinese National 
      Knowledge Infrastructure (CNKI) were systematically screened from inception to 
      November 2020 using the prespecified terms. Prospective trials (evaluating or) 
      comparing the efficacy of endostar combined with CCRT and CCRT for locally 
      advanced NSCLC were included. The primary endpoints were risk ratios (RRs) for 
      objective response rate (ORR) and disease control rate (DCR). The secondary 
      endpoints were RRs for overall survival (OS) and adverse events (AEs). RESULTS: 
      Ten studies with 716 patients were included in this meta-analysis. Endostar 
      combined with CCRT significantly improved ORR and DCR compared with CCRT. The RRs 
      of ORR and DCR for endostar combined with CCRT versus CCRT were 1.263 (95% CI: 
      1.137-1.403, p < 0.001) and 1.274 (95% CI: 1.124-1.444, p < 0.001), respectively. 
      Endostar combined with CCRT significantly improved one-year survival rate 
      compared with CCRT with pooled RR = 1.113 (95% CI: 1.006-1.231, p = 0.038). 
      Endostar combination treatments had similar incidences of main adverse events 
      compared with CCRT (p > 0.05). CONCLUSION: Endostar combined with CCRT is 
      associated with significantly higher ORR, DCR and survival rate than CCRT with 
      similar incidences of main adverse events in NSCLC.
CI  - (c) 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Yuan, Meng
AU  - Yuan M
AUID- ORCID: 0000-0001-7704-8633
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Zhai, Yirui
AU  - Zhai Y
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Men, Yu
AU  - Men Y
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
AD  - Department of VIP Medical Services, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Wang, Jianyang
AU  - Wang J
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Deng, Lei
AU  - Deng L
AUID- ORCID: 0000-0001-5919-5074
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Wang, Wenqing
AU  - Wang W
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Bao, Yongxing
AU  - Bao Y
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Yang, Xu
AU  - Yang X
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Sun, Shuang
AU  - Sun S
AUID- ORCID: 0000-0002-1274-0087
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Ma, Zeliang
AU  - Ma Z
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Liu, Yunsong
AU  - Liu Y
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Wang, Jun
AU  - Wang J
AUID- ORCID: 0000-0002-9733-1433
AD  - Department of Radiation Oncology, The Fourth Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Zhu, Hui
AU  - Zhu H
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, China.
FAU - Hui, Zhouguang
AU  - Hui Z
AUID- ORCID: 0000-0002-7189-4692
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
AD  - Department of VIP Medical Services, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20211021
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Endostatins)
RN  - 0 (Recombinant Proteins)
RN  - GVG18ZDN65 (endostar protein)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*therapy
MH  - Chemoradiotherapy/*methods
MH  - Combined Modality Therapy
MH  - Endostatins/*therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*therapy
MH  - Recombinant Proteins
MH  - Survival Rate
PMC - PMC8636201
OTO - NOTNLM
OT  - NSCLC
OT  - chemoradiotherapy
OT  - endostar
OT  - meta-analysis
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this manuscript.
EDAT- 2021/10/23 06:00
MHDA- 2022/02/01 06:00
PMCR- 2021/12/01
CRDT- 2021/10/22 07:12
PHST- 2021/09/25 00:00 [revised]
PHST- 2021/09/20 00:00 [received]
PHST- 2021/09/29 00:00 [accepted]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/10/22 07:12 [entrez]
PHST- 2021/12/01 00:00 [pmc-release]
AID - TCA14188 [pii]
AID - 10.1111/1759-7714.14188 [doi]
PST - ppublish
SO  - Thorac Cancer. 2021 Dec;12(23):3208-3215. doi: 10.1111/1759-7714.14188. Epub 2021 
      Oct 21.